Genopole and research laboratories

D4MedTech:a Tiers-Lieux d’Expérimentation to reinvent the care itinerary in diabetology

In December 2024, Genopole was chosen as a laureate of the Tiers-Lieux d’Expérimentation call for proposals in eHealth, a part of the national France 2030 strategy. This call provides funding to entities in France able to respond to a current lack of eHealth experimental facilities in the country. With D4MedTech, the Essonne biocluster is thus launching a structuring initiative for the use of digital technologies to bring innovation in diabetology and a transformation of medical practices for the benefit of patients.

This Tiers-Lieu functions within the dynamic of "5P" medicine—preventive, predictive, participative, personalized and pertinent—and responds to the increasing need for technological tools to prevent diabetes or monitor and accompany the patients who are living with it. Within a collaborative framework uniting researchers, clinicians, businesses and patients, D4MedTech's purpose is to accelerate the development of concrete and clinically validated solutions to meet the needs of diabetes patients in the Essonne territory.

Two pilot projects with ambitious objectives

D4MedTech is currently forwarding two, potentially high-impact experimental projects:

PREDIDIAB is aimed at the early prediction of type-2 diabetes risk in young adults via an algorithm integrating salivary test results and a personalized questionnaire. The project's objective is to detect risks before diabetes manifests and establish targeted prevention strategies. The PREDIDIAB team plans to ultimately pursue CE marking for its technology to allow its large-scale deployment.
MFDeep seeks to address fetal macrosomia, a pregnancy complication made more frequent by gestational diabetes. By combining ultrasound data, continuously monitored physiological data and insulin assay, this project hopes to furnish a reliable decision aid for obstetricians. Its objective is to reduce unnecessary preterm birth for the good of mother and baby.

The vocation of D4MedTech is to accelerate the development of concrete and clinically validated solutions.

An ecosystem mobilized for health innovation

D4MedTech's success is built upon strong teamwork between public and private actors. The project calls notably on the South Île-de-France Medical Center (CHSF), the Center for Studies and Research for the Intensification of Diabetes Treatment, (CERITD), EIT Health France and the SATT Paris-Saclay to bring about solutions tested in real-life conditions to genuinely respond to the needs of caregivers and patients.

By favoring codevelopment and experimentation, D4MedTech intends to accelerate the transfer of lab innovation to healthcare provision, strengthen eHealth business competitiveness and consolidate France's place in digital technologies for health.